3347.HK Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 11:08):

Stats
Объем за сегодня	4.75M
Средний объем	2.60M
Рыночная капитализация	41.20B
EPS	HKD0.562 ( 2023-09-30 )
Last Dividend	HKD0.616 ( 2023-05-25 )
Next Dividend	HKD0 ( N/A )
P/E	13.28
ATR14	HKD0.0940 (0.28%)

Объем Корреляция

Длинно: -0.06 (neutral)

Кратко: -0.15 (neutral)

Signal:(61.483) Neutral

Hangzhou Tigermed Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Hangzhou Tigermed Корреляция - Валюта/Сырье

-0.06
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.10
( neutral )

0.15
( neutral )

-0.35
( neutral )

Hangzhou Tigermed Финансовые показатели

Annual	2023
Выручка:	HKD7.38B
Валовая прибыль:	HKD2.85B (38.58 %)
EPS:	HKD2.34

FY	2023
Выручка:	HKD7.38B
Валовая прибыль:	HKD2.85B (38.58 %)
EPS:	HKD2.34

FY	2022
Выручка:	HKD7.09B
Валовая прибыль:	HKD2.81B (39.64 %)
EPS:	HKD2.32

FY	2021
Выручка:	HKD5.21B
Валовая прибыль:	HKD2.27B (43.55 %)
EPS:	HKD3.31

Financial Reports:

No articles found.

Hangzhou Tigermed Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.616 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Hangzhou Tigermed Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.20 - good (82.03%) | Divividend Growth Potential Score: 5.20 - Stable (4.03%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.362	2021-05-25
Last Dividend	HKD0.616	2023-05-25
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD1.557	--
Avg. Dividend % Per Year	0.00%	--
Score	2.54	--
Div. Sustainability Score	8.20
Div.Growth Potential Score	5.20
Div. Directional Score	6.70	--

Next Divdend (Est)
(2025-03-31)

HKD0.652 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.54

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1523.HK	Ex Dividend Knight	2023-08-09	Semi-Annually	0.00%
0573.HK	Ex Dividend Junior	2023-10-05	Annually	0.00%
8476.HK	Ex Dividend Knight	2023-08-22	Annually	0.00%
2039.HK	Ex Dividend Junior	2023-07-25	Annually	0.00%
1109.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
0175.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
3788.HK	Ex Dividend Knight	2023-10-05	Annually	0.00%
1681.HK	Ex Dividend Knight	2023-06-08	Semi-Annually	0.00%
0716.HK	Ex Dividend Junior	2023-09-11	Annually	0.00%
2233.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.274	1.500	4.52	6.77	[0 - 0.5]
returnOnAssetsTTM	0.0682	1.200	7.73	9.27	[0 - 0.3]
returnOnEquityTTM	0.0978	1.500	-0.0245	-0.0367	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	2.74	0.800	1.295	1.036	[1 - 3]
quickRatioTTM	2.71	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.793	1.500	1.151	1.727	[0.2 - 2]
debtRatioTTM	0.114	-1.500	8.10	-10.00	[0 - 0.6]
interestCoverageTTM	-8 465.38	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	1.951	2.00	9.35	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.589	2.00	9.21	10.00	[0 - 20]
debtEquityRatioTTM	0.161	-1.500	9.35	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.386	1.000	6.90	6.90	[0.2 - 0.8]
operatingProfitMarginTTM	0.337	1.000	5.26	5.26	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.499	1.000	8.34	8.34	[0.2 - 2]
assetTurnoverTTM	0.249	0.800	-1.675	-1.340	[0.5 - 2]
Total Score				8.20

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.30	1.000	8.76	0	[1 - 100]
returnOnEquityTTM	0.0978	2.50	-0.0157	-0.0367	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.589	2.00	9.47	10.00	[0 - 30]
dividendYielPercentageTTM	1.980	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.951	2.00	9.35	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	0.152	1.500	-2.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.229	1.000	6.78	0	[0.1 - 0.5]
Total Score				5.20

Hangzhou Tigermed

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.